Prevention & lipidsCohort study
PCSK9 inhibitor treatment and outcomes in patients with atherosclerotic cardiovascular disease but without prior ischaemic events: an observational study
- Retrospective cohort study
- propensity-score matched
- 1:2 matching
Authors' conclusion
In ASCVD patients without prior events in clinical practice, PCSK9i mAb treatment was associated with lower ischaemic event and mortality rates.
Study context
- Population
- Patients with atherosclerotic CVD without prior ischaemic events, Optum Research Database, 2016–2022matched cohort
- Participants
- 19,670 patients
- Exposure
- PCSK9i monoclonal antibodies (mAb) initiation vs non-initiation
- PCSK9i mAbn = 6,545
- Non-initiatorsn = 13,125reference
- Outcome
- Composite of:
- Non-fatal MI
- Non-fatal ischaemic stroke
- All-cause mortality
- Follow-up
- 5 years
Main finding
As reported in the abstract
- PCSK9i mAb
- Relative risk reduction (RRR) 30.9%
- PCSK9i mAb
- Absolute risk reduction (ARR) 7.8%
Observational data: associations, not effects.
Further findings
Individual endpoints (RRR) · 5 years
- RRR, MI
- 28.3%
- RRR, ischaemic stroke
- 26.4%
- RRR, all-cause mortality
- 28.5%
- MI P < .0001
- Ischaemic stroke P = .02
- All-cause mortality P < .0001
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
PCSK9 inhibitor treatment and outcomes in patients with atherosclerotic cardiovascular disease but without prior ischaemic events: an observational study. Eur Heart J. Published 16 April 2026. doi:10.1093/eurheartj/ehag176
Summarised from the published abstract; every number is checked against it